Literature DB >> 23795941

IFN-γ stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro.

Cariosa Noone1, Anthony Kihm, Karen English, Shirley O'Dea, Bernard P Mahon.   

Abstract

Umbilical cord tissue represents a unique source of cells with potential for cell therapy applications for multiple diseases. Human umbilical tissue-derived cells (hUTC) are a developmentally early stage, homogenous population of cells that are HLA-ABC dim, HLA-DR negative, and lack expression of co-stimulatory molecules in the unactivated state. The lack of HLA-DR and co-stimulatory molecule expression on unactivated hUTC may account for their reduced immunogenicity, facilitating their use in allogeneic settings. However, such approaches could be confounded by host innate cells such as natural killer (NK) cells. Here, we evaluate in vitro NK cell interactions with hUTC and compare them with human mesenchymal stem cells (MSC). Our investigations show that hUTC suppress NK activation, through prostaglandin-E2 secretion in a contact-independent manner. Prestimulation of hUTC or human MSC with interferon gamma (IFN-γ) induced expression of the tryptophan degrading enzyme indoleamine 2, 3 dioxygenase, facilitating enhanced suppression. However, resting NK cells of different killer immunoglobulin-like receptor haplotypes did not kill hUTC or MSC; only activated NK cells had the ability to kill nonstimulated hUTC and, to a lesser extent, MSC. The cell killing process involved signaling through the NKG2D receptor and the perforin/granzyme pathway; this was supported by CD54 (ICAM-1) expression by hUTC. IFN-γ-stimulated hUTC or hMSC were less susceptible to NK killing; in this case, protection was associated with elevated HLA-ABC expression. These data delineate the different mechanisms in a two-way interaction between NK cells and two distinct cell therapies, hUTC or hMSC, and how these interactions may influence their clinical applications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23795941      PMCID: PMC3824722          DOI: 10.1089/scd.2013.0028

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  47 in total

1.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Authors:  Katarina Le Blanc; Ida Rasmusson; Berit Sundberg; Cecilia Götherström; Moustapha Hassan; Mehmet Uzunel; Olle Ringdén
Journal:  Lancet       Date:  2004-05-01       Impact factor: 79.321

Review 2.  Mesenchymal stem cells: clinical applications and biological characterization.

Authors:  Frank P Barry; J Mary Murphy
Journal:  Int J Biochem Cell Biol       Date:  2004-04       Impact factor: 5.085

Review 3.  Activation and function of natural killer cell responses during viral infections.

Authors:  C A Biron
Journal:  Curr Opin Immunol       Date:  1997-02       Impact factor: 7.486

Review 4.  Receptors for HLA class-I molecules in human natural killer cells.

Authors:  A Moretta; C Bottino; M Vitale; D Pende; R Biassoni; M C Mingari; L Moretta
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

Review 5.  NK cell receptors.

Authors:  L L Lanier
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

6.  Multilineage potential of adult human mesenchymal stem cells.

Authors:  M F Pittenger; A M Mackay; S C Beck; R K Jaiswal; R Douglas; J D Mosca; M A Moorman; D W Simonetti; S Craig; D R Marshak
Journal:  Science       Date:  1999-04-02       Impact factor: 47.728

7.  Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

Authors:  K Kärre; H G Ljunggren; G Piontek; R Kiessling
Journal:  Nature       Date:  1986 Feb 20-26       Impact factor: 49.962

8.  Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells.

Authors:  J M Ryan; F Barry; J M Murphy; B P Mahon
Journal:  Clin Exp Immunol       Date:  2007-05-22       Impact factor: 4.330

9.  Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy.

Authors:  Arman T Askari; Samuel Unzek; Zoran B Popovic; Corey K Goldman; Farhad Forudi; Matthew Kiedrowski; Aleksandr Rovner; Stephen G Ellis; James D Thomas; Paul E DiCorleto; Eric J Topol; Marc S Penn
Journal:  Lancet       Date:  2003-08-30       Impact factor: 79.321

Review 10.  Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

Authors:  A Moretta; C Bottino; M Vitale; D Pende; C Cantoni; M C Mingari; R Biassoni; L Moretta
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

View more
  44 in total

1.  Gene delivery with IFN-γ-expression plasmids enhances the therapeutic effects of MSCs on DSS-induced mouse colitis.

Authors:  Yueqiu Chen; Yuxian Song; Huishuang Miao; Yujun Xu; Mingming Lv; Tingting Wang; Yayi Hou
Journal:  Inflamm Res       Date:  2015-07-08       Impact factor: 4.575

Review 2.  The influence of macrophages on mesenchymal stromal cell therapy: passive or aggressive agents?

Authors:  F Carty; B P Mahon; K English
Journal:  Clin Exp Immunol       Date:  2017-02-20       Impact factor: 4.330

3.  Immunological impact of Wharton's Jelly mesenchymal stromal cells and natural killer cell co-culture.

Authors:  Mehdi Najar; Mohammad Fayyad-Kazan; Nathalie Meuleman; Dominique Bron; Hussein Fayyad-Kazan; Laurence Lagneaux
Journal:  Mol Cell Biochem       Date:  2018-01-30       Impact factor: 3.396

4.  Mesenchymal stromal cells of the bone marrow and natural killer cells: cell interactions and cross modulation.

Authors:  Mehdi Najar; Mohammad Fayyad-Kazan; Nathalie Meuleman; Dominique Bron; Hussein Fayyad-Kazan; Laurence Lagneaux
Journal:  J Cell Commun Signal       Date:  2018-01-19       Impact factor: 5.782

Review 5.  Stem cell-based therapy for human diseases.

Authors:  Duc M Hoang; Phuong T Pham; Trung Q Bach; Anh T L Ngo; Quyen T Nguyen; Trang T K Phan; Giang H Nguyen; Phuong T T Le; Van T Hoang; Nicholas R Forsyth; Michael Heke; Liem Thanh Nguyen
Journal:  Signal Transduct Target Ther       Date:  2022-08-06

Review 6.  Translating MSC Therapy in the Age of Obesity.

Authors:  Lauren Boland; Laura Melanie Bitterlich; Andrew E Hogan; James A Ankrum; Karen English
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

Review 7.  Significance of Placental Mesenchymal Stem Cell in Placenta Development and Implications for Preeclampsia.

Authors:  Yang Zhang; Yanqi Zhong; Li Zou; Xiaoxia Liu
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

8.  Hepatocyte Growth Factor Is Required for Mesenchymal Stromal Cell Protection Against Bleomycin-Induced Pulmonary Fibrosis.

Authors:  Emer F Cahill; Helen Kennelly; Fiona Carty; Bernard P Mahon; Karen English
Journal:  Stem Cells Transl Med       Date:  2016-07-07       Impact factor: 6.940

Review 9.  Mesenchymal stem cell-derived extracellular vesicles in the failing heart: past, present, and future.

Authors:  Catherine Karbasiafshar; Frank W Sellke; M Ruhul Abid
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-04-16       Impact factor: 4.733

Review 10.  Mesenchymal Stromal Cells: Updates and Therapeutic Outlook in Rheumatic Diseases.

Authors:  Yves-Marie Pers; Christian Jorgensen
Journal:  J Clin Med       Date:  2013-10-23       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.